About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Unusual Presentation of Papillary Renal Cell Carcinoma

asthma rescue inhaler

otc inhalers for copd read here
Ajay Kumar G1, Nerli RB1, P. Malur2
From the 1Department of Urology, KLES Kidney Foundation, 2Department of Pathology,  KLE University’s JN Medical College,  KLES Dr Prabhakar Kore Hospital & MRC, Belgaum, India 590010. 
Corresponding Author:
Dr. Ajay Kumar G
Email: drajay707@gmail.com
Received: 22-APR-2014 Accepted: 17-JUL-2014 Published Online: 20-AUG-2014
DOI: http://dx.doi.org/10.17659/01.2014.0078
Abstract
Papillary renal cell carcinoma (pRCC) is the second most frequent renal cell carcinoma (RCC) subtype, accounting for approximately 13–15% of all known RCC lesions. We report a case of papillary renal cell carcinoma presented clinically and radiologically like that of a transitional cell carcinoma of renal pelvis in a 62 year old male.
Keywords : Kidney, Renal cell carcinoma, Flank Pain, Hematuria, Kidney Neoplasms, Abdomen.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Mar 17, 2025